HomeBCRX • BMV
add
BioCryst Pharmaceuticals Inc
Previous close
$118.00
Year range
$118.00 - $215.00
Market cap
2.17B USD
Avg Volume
28.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
In the news
Financials
Income Statement
Revenue
Net income
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Revenue | 406.56M | 209.09% |
Operating expense | 136.65M | 69.81% |
Net income | 245.84M | 1,017.50% |
Net profit margin | 60.47 | 396.86% |
Earnings per share | — | — |
EBITDA | 260.72M | 10,815.99% |
Effective tax rate | 0.88% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | — | — |
Total assets | — | — |
Total liabilities | — | — |
Total equity | — | — |
Shares outstanding | — | — |
Price to book | — | — |
Return on assets | — | — |
Return on capital | 220.50% | — |
Cash Flow
Net change in cash
| (USD) | Dec 2025info | Y/Y change |
|---|---|---|
Net income | 245.84M | 1,017.50% |
Cash from operations | — | — |
Cash from investing | — | — |
Cash from financing | — | — |
Net change in cash | — | — |
Free cash flow | — | — |
About
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a late stage biotech company that focuses on oral drugs for rare and serious diseases. BioCryst's antiviral drug peramivir was approved by FDA in December 2014. It has also been approved in Japan, Korea, and China. Wikipedia
Founded
1986
Headquarters
Website
Employees
435
